With a start in 2001, Hunt has continually pursued companies with clinical efficacy data or strong human proxy data, which has typically meant companies with products in various stages of clinical trials. Although this later-stage approach will always be core to Hunt’s investment strategy, Hunt will occasionally pursue pre-clinical opportunities, especially those with exceptional management teams.

Another important component of the strategy is to invest alongside other experienced life science investors in either a “co-lead” or “follower” manner. In addition to the underlying intellectual property and market focus, Hunt concentrates heavily on each member of the management team as Hunt believes people are the most critical component of any company. Finally, although Hunt operates much like a fund, it does not manage third party capital but instead invests capital generated by other Hunt affiliates. Hunt invests $2-7 million per round of a company’s evolution with no ceiling on the total capital invested in any one company.